UniProt ID | SRPK1_HUMAN | |
---|---|---|
UniProt AC | Q96SB4 | |
Protein Name | SRSF protein kinase 1 | |
Gene Name | SRPK1 {ECO:0000312|EMBL:CAC39299.1} | |
Organism | Homo sapiens (Human). | |
Sequence Length | 655 | |
Subcellular Localization | Isoform 2: Cytoplasm. Nucleus. Nucleus matrix. Microsome. Shuttles between the nucleus and the cytoplasm. Inhibition of the Hsp90 ATPase activity, osmotic stress and interaction with HHV-1 ICP27 protein can induce its translocation to the nucleus. KA | |
Protein Description | Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is involved in the phosphorylation of SR splicing factors and the regulation of splicing. Plays a central role in the regulatory network for splicing, controlling the intranuclear distribution of splicing factors in interphase cells and the reorganization of nuclear speckles during mitosis. Can influence additional steps of mRNA maturation, as well as other cellular activities, such as chromatin reorganization in somatic and sperm cells and cell cycle progression. Isoform 2 phosphorylates SFRS2, ZRSR2, LBR and PRM1. Isoform 2 phosphorylates SRSF1 using a directional (C-terminal to N-terminal) and a dual-track mechanism incorporating both processive phosphorylation (in which the kinase stays attached to the substrate after each round of phosphorylation) and distributive phosphorylation steps (in which the kinase and substrate dissociate after each phosphorylation event). The RS domain of SRSF1 binds first to a docking groove in the large lobe of the kinase domain of SRPK1. This induces certain structural changes in SRPK1 and/or RRM2 domain of SRSF1, allowing RRM2 to bind the kinase and initiate phosphorylation. The cycles continue for several phosphorylation steps in a processive manner (steps 1-8) until the last few phosphorylation steps (approximately steps 9-12). During that time, a mechanical stress induces the unfolding of the beta-4 motif in RRM2, which then docks at the docking groove of SRPK1. This also signals RRM2 to begin to dissociate, which facilitates SRSF1 dissociation after phosphorylation is completed. Isoform 2 can mediate hepatitis B virus (HBV) core protein phosphorylation. It plays a negative role in the regulation of HBV replication through a mechanism not involving the phosphorylation of the core protein but by reducing the packaging efficiency of the pregenomic RNA (pgRNA) without affecting the formation of the viral core particles. Isoform 1 and isoform 2 can induce splicing of exon 10 in MAPT/TAU. The ratio of isoform 1/isoform 2 plays a decisive role in determining cell fate in K-562 leukaemic cell line: isoform 2 favors proliferation where as isoform 1 favors differentiation.. | |
Protein Sequence | MERKVLALQARKKRTKAKKDKAQRKSETQHRGSAPHSESDLPEQEEEILGSDDDEQEDPNDYCKGGYHLVKIGDLFNGRYHVIRKLGWGHFSTVWLSWDIQGKKFVAMKVVKSAEHYTETALDEIRLLKSVRNSDPNDPNREMVVQLLDDFKISGVNGTHICMVFEVLGHHLLKWIIKSNYQGLPLPCVKKIIQQVLQGLDYLHTKCRIIHTDIKPENILLSVNEQYIRRLAAEATEWQRSGAPPPSGSAVSTAPQPKPADKMSKNKKKKLKKKQKRQAELLEKRMQEIEEMEKESGPGQKRPNKQEESESPVERPLKENPPNKMTQEKLEESSTIGQDQTLMERDTEGGAAEINCNGVIEVINYTQNSNNETLRHKEDLHNANDCDVQNLNQESSFLSSQNGDSSTSQETDSCTPITSEVSDTMVCQSSSTVGQSFSEQHISQLQESIRAEIPCEDEQEQEHNGPLDNKGKSTAGNFLVNPLEPKNAEKLKVKIADLGNACWVHKHFTEDIQTRQYRSLEVLIGSGYNTPADIWSTACMAFELATGDYLFEPHSGEEYTRDEDHIALIIELLGKVPRKLIVAGKYSKEFFTKKGDLKHITKLKPWGLFEVLVEKYEWSQEEAAGFTDFLLPMLELIPEKRATAAECLRHPWLNS | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
4 | Ubiquitination | ----MERKVLALQAR ----CHHHHHHHHHH | 28.44 | 21890473 | |
4 | Ubiquitination | ----MERKVLALQAR ----CHHHHHHHHHH | 28.44 | 21890473 | |
4 (in isoform 2) | Ubiquitination | - | 28.44 | 21890473 | |
4 | Acetylation | ----MERKVLALQAR ----CHHHHHHHHHH | 28.44 | 164347 | |
12 | Acetylation | VLALQARKKRTKAKK HHHHHHHHHHHHHHH | 50.01 | 164349 | |
13 | Acetylation | LALQARKKRTKAKKD HHHHHHHHHHHHHHH | 60.80 | 164351 | |
16 | Acetylation | QARKKRTKAKKDKAQ HHHHHHHHHHHHHHH | 63.34 | 164353 | |
18 | Ubiquitination | RKKRTKAKKDKAQRK HHHHHHHHHHHHHHH | 64.16 | 24816145 | |
18 (in isoform 3) | Phosphorylation | - | 64.16 | - | |
26 | Phosphorylation | KDKAQRKSETQHRGS HHHHHHHHHHCCCCC | 48.33 | 27422710 | |
28 | Phosphorylation | KAQRKSETQHRGSAP HHHHHHHHCCCCCCC | 36.44 | 27422710 | |
33 | Phosphorylation | SETQHRGSAPHSESD HHHCCCCCCCCCCCC | 38.29 | 23927012 | |
37 | Phosphorylation | HRGSAPHSESDLPEQ CCCCCCCCCCCCCHH | 37.42 | 26503892 | |
39 | Phosphorylation | GSAPHSESDLPEQEE CCCCCCCCCCCHHHH | 47.68 | 23927012 | |
51 | Phosphorylation | QEEEILGSDDDEQED HHHHHHCCCCCCCCC | 34.13 | 20201521 | |
62 | Phosphorylation | EQEDPNDYCKGGYHL CCCCCCCCCCCCEEE | 11.60 | 23927012 | |
67 | Phosphorylation | NDYCKGGYHLVKIGD CCCCCCCEEEEEEHH | 10.72 | 23312004 | |
109 | Acetylation | GKKFVAMKVVKSAEH CCEEEEEEEECCCCH | 33.85 | 26051181 | |
113 | Phosphorylation | VAMKVVKSAEHYTET EEEEEECCCCHHHHH | 27.55 | 24719451 | |
117 | Phosphorylation | VVKSAEHYTETALDE EECCCCHHHHHHHHH | 9.58 | 24719451 | |
118 | Phosphorylation | VKSAEHYTETALDEI ECCCCHHHHHHHHHH | 28.85 | 24719451 | |
134 | Phosphorylation | LLKSVRNSDPNDPNR HHHHHHCCCCCCCCH | 43.83 | - | |
143 | Sulfoxidation | PNDPNREMVVQLLDD CCCCCHHHHHHHHHC | 3.02 | 21406390 | |
154 | Phosphorylation | LLDDFKISGVNGTHI HHHCCEEECCCCCEE | 36.96 | 30631047 | |
159 | Phosphorylation | KISGVNGTHICMVFE EEECCCCCEEEHHHH | 11.67 | 30631047 | |
174 | Ubiquitination | VLGHHLLKWIIKSNY HHHHHHHHHHHHCCC | 42.58 | 22817900 | |
178 | Ubiquitination | HLLKWIIKSNYQGLP HHHHHHHHCCCCCCC | 24.42 | 22817900 | |
215 | Ubiquitination | RIIHTDIKPENILLS EEEECCCCHHHEEEE | 49.44 | 32015554 | |
215 | Acetylation | RIIHTDIKPENILLS EEEECCCCHHHEEEE | 49.44 | 26051181 | |
222 | Phosphorylation | KPENILLSVNEQYIR CHHHEEEECCHHHHH | 21.32 | 12565829 | |
238 (in isoform 3) | Phosphorylation | - | 8.43 | 27642862 | |
249 | Phosphorylation | GAPPPSGSAVSTAPQ CCCCCCCCCCCCCCC | 29.81 | - | |
252 | Phosphorylation | PPSGSAVSTAPQPKP CCCCCCCCCCCCCCC | 20.68 | - | |
253 | Phosphorylation | PSGSAVSTAPQPKPA CCCCCCCCCCCCCCC | 35.44 | 28555341 | |
258 | Acetylation | VSTAPQPKPADKMSK CCCCCCCCCCHHCCH | 47.81 | 26051181 | |
268 | Ubiquitination | DKMSKNKKKKLKKKQ HHCCHHHHHHHHHHH | 65.61 | - | |
284 | Ubiquitination | RQAELLEKRMQEIEE HHHHHHHHHHHHHHH | 53.81 | 24816145 | |
286 | Sulfoxidation | AELLEKRMQEIEEME HHHHHHHHHHHHHHH | 6.58 | 21406390 | |
288 (in isoform 3) | Phosphorylation | - | 42.92 | 27642862 | |
296 | Phosphorylation | IEEMEKESGPGQKRP HHHHHHHHCCCCCCC | 62.45 | 23403867 | |
305 | Acetylation | PGQKRPNKQEESESP CCCCCCCCCCCCCCC | 62.87 | 26051181 | |
309 | Phosphorylation | RPNKQEESESPVERP CCCCCCCCCCCCCCC | 42.49 | 29255136 | |
311 | Phosphorylation | NKQEESESPVERPLK CCCCCCCCCCCCCCC | 43.45 | 29255136 | |
318 | Acetylation | SPVERPLKENPPNKM CCCCCCCCCCCCCCC | 59.12 | 26051181 | |
326 | Phosphorylation | ENPPNKMTQEKLEES CCCCCCCCHHHHHHC | 34.87 | 26074081 | |
333 | Phosphorylation | TQEKLEESSTIGQDQ CHHHHHHCCCCCCCC | 24.33 | 21815630 | |
334 | Phosphorylation | QEKLEESSTIGQDQT HHHHHHCCCCCCCCC | 27.59 | 25159151 | |
335 | Phosphorylation | EKLEESSTIGQDQTL HHHHHCCCCCCCCCC | 38.10 | 30576142 | |
341 | Phosphorylation | STIGQDQTLMERDTE CCCCCCCCCCCCCCC | 36.04 | 28555341 | |
343 | Sulfoxidation | IGQDQTLMERDTEGG CCCCCCCCCCCCCCC | 4.51 | 21406390 | |
365 | Phosphorylation | GVIEVINYTQNSNNE CEEEEEEEECCCCCC | 9.89 | - | |
373 | Phosphorylation | TQNSNNETLRHKEDL ECCCCCCCEECHHHH | 31.08 | - | |
393 | Phosphorylation | CDVQNLNQESSFLSS CCCCCCCHHHHHHHH | 55.93 | 18669648 | |
432 | O-linked_Glycosylation | MVCQSSSTVGQSFSE EEEECCCCCCCCCCH | 30.51 | OGP | |
456 | Ubiquitination | IRAEIPCEDEQEQEH HHCCCCCCCHHHHHH | 60.26 | - | |
470 | Acetylation | HNGPLDNKGKSTAGN HCCCCCCCCCCCCCC | 68.34 | 26051181 | |
470 | Ubiquitination | HNGPLDNKGKSTAGN HCCCCCCCCCCCCCC | 68.34 | 32015554 | |
472 | Ubiquitination | GPLDNKGKSTAGNFL CCCCCCCCCCCCCCC | 46.36 | 27667366 | |
478 | Ubiquitination | GKSTAGNFLVNPLEP CCCCCCCCCCCCCCC | 8.68 | - | |
480 | Phosphorylation | STAGNFLVNPLEPKN CCCCCCCCCCCCCCC | 6.41 | 17081983 | |
482 | Phosphorylation | AGNFLVNPLEPKNAE CCCCCCCCCCCCCHH | 30.53 | 17081983 | |
486 | Ubiquitination | LVNPLEPKNAEKLKV CCCCCCCCCHHHHCE | 60.46 | 29967540 | |
494 | Ubiquitination | NAEKLKVKIADLGNA CHHHHCEEEEHHCCC | 30.50 | - | |
506 | Ubiquitination | GNACWVHKHFTEDIQ CCCEEEEHHHCCCHH | 30.69 | - | |
506 | Acetylation | GNACWVHKHFTEDIQ CCCEEEEHHHCCCHH | 30.69 | - | |
509 | Phosphorylation | CWVHKHFTEDIQTRQ EEEEHHHCCCHHHHH | 32.25 | 23403867 | |
514 | Phosphorylation | HFTEDIQTRQYRSLE HHCCCHHHHHEEEEE | 21.77 | 29255136 | |
515 | Methylation | FTEDIQTRQYRSLEV HCCCHHHHHEEEEEE | 18.37 | - | |
555 | Phosphorylation | DYLFEPHSGEEYTRD CEEECCCCCCCCCCC | 59.63 | 12565829 | |
563 | Ubiquitination | GEEYTRDEDHIALII CCCCCCCHHHHHHHH | 48.47 | - | |
569 | Ubiquitination | DEDHIALIIELLGKV CHHHHHHHHHHHCCC | 1.37 | - | |
569 | Acetylation | DEDHIALIIELLGKV CHHHHHHHHHHHCCC | 1.37 | - | |
579 | Ubiquitination | LLGKVPRKLIVAGKY HHCCCCHHHECCCCC | 36.17 | 23000965 | |
585 | Acetylation | RKLIVAGKYSKEFFT HHHECCCCCCHHHCC | 36.29 | 19608861 | |
585 (in isoform 2) | Ubiquitination | - | 36.29 | 21890473 | |
585 | Ubiquitination | RKLIVAGKYSKEFFT HHHECCCCCCHHHCC | 36.29 | 23000965 | |
587 | Phosphorylation | LIVAGKYSKEFFTKK HECCCCCCHHHCCCC | 29.24 | - | |
588 | Ubiquitination | IVAGKYSKEFFTKKG ECCCCCCHHHCCCCC | 56.29 | 23000965 | |
604 | Ubiquitination | LKHITKLKPWGLFEV HHHEEECCCCCHHHH | 40.04 | - | |
726 | Phosphorylation | ------------------------------------------------------------------------------ ------------------------------------------------------------------------------ | 12565829 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
33 | S | Phosphorylation | Kinase | SRPK1 | Q96SB4 | PSP |
51 | S | Phosphorylation | Kinase | CSNK2A1 | P68400 | GPS |
51 | S | Phosphorylation | Kinase | CK2 | - | Uniprot |
51 | S | Phosphorylation | Kinase | CSNK2A2 | P19784 | GPS |
51 | S | Phosphorylation | Kinase | CSNK2B | - | GPS |
51 | S | Phosphorylation | Kinase | CK2-FAMILY | - | GPS |
222 | S | Phosphorylation | Kinase | CSK21 | P68400 | PhosphoELM |
222 | S | Phosphorylation | Kinase | CSK2B | P67870 | PhosphoELM |
309 | S | Phosphorylation | Kinase | SRPK1 | Q96SB4 | PSP |
326 | T | Phosphorylation | Kinase | SRPK1 | Q96SB4 | PSP |
555 | S | Phosphorylation | Kinase | CK2 | - | Uniprot |
555 | S | Phosphorylation | Kinase | CSNK2B | - | GPS |
555 | S | Phosphorylation | Kinase | CK2-FAMILY | - | GPS |
555 | S | Phosphorylation | Kinase | CSNK2A2 | P19784 | GPS |
555 | S | Phosphorylation | Kinase | CSNK2A1 | P68400 | GPS |
587 | S | Phosphorylation | Kinase | SRPK1 | Q96SB4 | PSP |
726 | S | Phosphorylation | Kinase | CSK2B | P67870 | PhosphoELM |
726 | S | Phosphorylation | Kinase | CSK21 | P68400 | PhosphoELM |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of SRPK1_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of SRPK1_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-585, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51, AND MASSSPECTROMETRY. | |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-51; SER-309 ANDSER-311, AND MASS SPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51; SER-309 AND SER-311,AND MASS SPECTROMETRY. | |
"Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column."; Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.; Anal. Sci. 24:161-166(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-309, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51; SER-309 AND SER-311,AND MASS SPECTROMETRY. | |
"Protein kinase CK2 phosphorylates and activates the SR protein-specific kinase 1."; Mylonis I., Giannakouros T.; Biochem. Biophys. Res. Commun. 301:650-656(2003). Cited for: ENZYME REGULATION, PHOSPHORYLATION AT SER-51 AND SER-555, ANDMUTAGENESIS OF SER-37; SER-51; SER-222; SER-311; SER-436; SER-555 ANDSER-619. |